Patents by Inventor Eustache Paramithiotis
Eustache Paramithiotis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220326236Abstract: This disclosure describes markers that are associated with active tuberculosis (TB) and demonstrates that the disclosed markers can be used as a biomarker for determining whether a subject has or is at risk of having active TB and for the early detection of HIV-associated TB. This disclosure also provides methods of screening subjects who are thought to be at risk for developing active TB, methods of determining the efficacy of therapeutic regimens for preventing or treating active TB, and methods of identifying anti-TB agents.Type: ApplicationFiled: October 2, 2020Publication date: October 13, 2022Applicant: Albert Einstein College of MedicineInventors: Jacqueline M. Achkar, Eustache Paramithiotis
-
Patent number: 10935549Abstract: The present invention provides biomarkers, methods and kits for diagnosing latent tuberculosis (TB) in a subject exposed to TB, and methods and kits for monitoring the effectiveness of treatment for latent TB.Type: GrantFiled: January 14, 2019Date of Patent: March 2, 2021Assignees: Caption Biosciences Inc., Case Western Reserve UniversityInventors: Eustache Paramithiotis, W. Henry Boom, Charles Bark
-
Publication number: 20190277846Abstract: The present invention provides biomarkers, methods and kits for diagnosing latent tuberculosis (TB) in a subject exposed to TB, and methods and kits for monitoring the effectiveness of treatment for latent TB.Type: ApplicationFiled: January 14, 2019Publication date: September 12, 2019Inventors: Eustache Paramithiotis, W. Henry Boom, Charles Bark
-
Patent number: 10338081Abstract: The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject.Type: GrantFiled: July 30, 2015Date of Patent: July 2, 2019Assignees: Caprion Biosciences Inc., Adaerata, Limited Partnership, Val-Chum, Limited PartnershipInventors: Eustache Paramithiotis, Marc Prentki, Rèmi Rabasa-Lhoret, Pascal Croteau, Joel Lanoix, S.R. Murthy Madiraju, Èrik Joly
-
Patent number: 10191063Abstract: The present invention provides biomarkers, methods and kits for diagnosing a Brucellosis, Q-Fever, and/or Lyme Disease, methods and kits for monitoring the effectiveness of treatment for Brucellosis, Q-Fever, or Lyme Disease, as well as methods for identifying a compound that can treat Brucellosis, Q-Fever, and/or Lyme Disease reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat a Brucellosis, Q-Fever, and/or Lyme Disease.Type: GrantFiled: September 4, 2015Date of Patent: January 29, 2019Assignee: Caprion Proteomics Inc.Inventors: Eustache Paramithiotis, Pascal Croteau
-
Publication number: 20180172699Abstract: The present invention provides biomarkers, methods and kits for diagnosing active tuberculosis in a subject, methods and kits for monitoring the effectiveness of treatment for active TB, as well as methods for identifying a compound that can treat TB reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat active TB.Type: ApplicationFiled: November 16, 2017Publication date: June 21, 2018Inventors: Eustache Paramithiotis, Pascal Croteau, Jacqueline Michele Achkar
-
Patent number: 9857378Abstract: The present invention provides biomarkers, methods and kits for diagnosing active tuberculosis in a subject, methods and kits for monitoring the effectiveness of treatment for active TB, as well as methods for identifying a compound that can treat TB reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat active TB.Type: GrantFiled: August 26, 2015Date of Patent: January 2, 2018Assignees: Caprion Proteomics Inc., Albert Einstein College of Medicine, Inc.Inventors: Eustache Paramithiotis, Pascal Croteau, Jacqueline Michele Achkar
-
Publication number: 20160266140Abstract: The present invention provides biomarkers, methods and kits for diagnosing a Brucellosis, Q-Fever, and/or Lyme Disease, methods and kits for monitoring the effectiveness of treatment for Brucellosis, Q-Fever, or Lyme Disease, as well as methods for identifying a compound that can treat Brucellosis, Q-Fever, and/or Lyme Disease reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat a Brucellosis, Q-Fever, and/or Lyme Disease.Type: ApplicationFiled: September 4, 2015Publication date: September 15, 2016Inventors: Eustache Paramithiotis, Pascal Croteau
-
Publication number: 20160154005Abstract: The present invention provides biomarkers, methods and kits for diagnosing active tuberculosis in a subject, methods and kits for monitoring the effectiveness of treatment for active TB, as well as methods for identifying a compound that can treat TB reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat active TB.Type: ApplicationFiled: August 26, 2015Publication date: June 2, 2016Inventors: Eustache Paramithiotis, Pascal Croteau, Jacqueline Michele Achkar
-
Publication number: 20150330997Abstract: The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject.Type: ApplicationFiled: July 30, 2015Publication date: November 19, 2015Inventors: Eustache Paramithiotis, Marc Prentki, Rèmi Rabasa-Lhoret, Pascal Croteau, Joel Lanoix, S.R. Murthy Madiraju, Érik Joly
-
Publication number: 20140308242Abstract: The invention relates to biomarkers measurable in a human subject that have prognostic value with respect to efficacy of therapeutic treatments for Hepatitis C viral infection. The markers also are believed to have value for diagnosis liver health/liver damage.Type: ApplicationFiled: October 21, 2011Publication date: October 16, 2014Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Mark Andrew Fleming, Brain J. Hare, Daniel Chelsky, Rene Allard, Eustache Paramithiotis
-
Patent number: 7435540Abstract: The present invention features methods for identifying peptides that selectively bind to PrPSc or fragments thereof. The invention also features the use of such peptides in screening methods for the identification of candidate agents useful for the treatment of a prion disease.Type: GrantFiled: January 27, 2006Date of Patent: October 14, 2008Assignee: IDEXX CorporationInventors: Neil Cashman, Eustache Paramithiotis, Sylvie La Boissière, Robert Lawton, Susan Francoeur, legal representative, Lisa Estey, Marc Pinard, Greg Francoeur
-
Publication number: 20070269434Abstract: Surprisingly, the present inventors have discovered that expression of TAT-041 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-041 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-041 expression or activity, comprising: contacting a candidate compound with a TAT-041 and detecting the presence or absence of binding between said compound and said TAT-041, or detecting a change in TAT-041 expression or activity. Methods are also included for the identification of compounds that modulate TAT-041 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-041 expression or activity.Type: ApplicationFiled: January 31, 2007Publication date: November 22, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070220620Abstract: Surprisingly, the present inventors have discovered that expression of TAT-046 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-046 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-046 expression or activity, comprising: contacting a candidate compound with a TAT-046 and detecting the presence or absence of binding between said compound and said TAT-046, or detecting a change in TAT-046 expression or activity. Methods are also included for the identification of compounds that modulate TAT-046 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-046 expression or activity.Type: ApplicationFiled: January 31, 2007Publication date: September 20, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070192884Abstract: Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity.Type: ApplicationFiled: January 25, 2007Publication date: August 16, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070192886Abstract: Surprisingly, the present inventors have discovered that expression of TAT-044 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-044 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-044 expression or activity, comprising: contacting a candidate compound with a TAT-044 and detecting the presence or absence of binding between said compound and said TAT-044, or detecting a change in TAT-044 expression or activity. Methods are also included for the identification of compounds that modulate TAT-044 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-044 expression or activity.Type: ApplicationFiled: January 30, 2007Publication date: August 16, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070192887Abstract: Surprisingly, the present inventors have discovered that expression of TAT-042 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-042 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-042 expression or activity, comprising: contacting a candidate compound with a TAT-042 and detecting the presence or absence of binding between said compound and said TAT-042, or detecting a change in TAT-042 expression or activity. Methods are also included for the identification of compounds that modulate TAT-042 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-042 expression or activity.Type: ApplicationFiled: January 30, 2007Publication date: August 16, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070192885Abstract: Surprisingly, the present inventors have discovered that expression of TAT-039 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-039 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-039 expression or activity, comprising: contacting a candidate compound with a TAT-039 and detecting the presence or absence of binding between said compound and said TAT-039, or detecting a change in TAT-039 expression or activity. Methods are also included for the identification of compounds that modulate TAT-039 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-039 expression or activity.Type: ApplicationFiled: January 26, 2007Publication date: August 16, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070192883Abstract: Surprisingly, the present inventors have discovered that expression of TAT-028 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-028 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-028 expression or activity, comprising: contacting a candidate compound with a TAT-028 and detecting the presence or absence of binding between said compound and said TAT-028, or detecting a change in TAT-028 expression or activity. Methods are also included for the identification of compounds that modulate TAT-028 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-028 expression or activity.Type: ApplicationFiled: January 19, 2007Publication date: August 16, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
-
Publication number: 20070186295Abstract: Surprisingly, the present inventors have discovered that expression of TAT-036 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-036 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-036 expression or activity, comprising: contacting a candidate compound with a TAT-036 and detecting the presence or absence of binding between said compound and said TAT-036, or detecting a change in TAT-036 expression or activity. Methods are also included for the identification of compounds that modulate TAT-036 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-036 expression or activity.Type: ApplicationFiled: January 24, 2007Publication date: August 9, 2007Inventors: Daniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo